Huaming Tan

Appearances

ETRASIMOD INDUCTION THERAPY IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A PHASE 2, RANDOMIZED, DOUBLE-BLIND SUBSTUDY
Date
May 9, 2023
BACKGROUND: After successful induction, a subset of patients with Crohn’s disease (CD) experience a secondary loss of response (LoR) to ustekinumab (UST) maintenance therapy. Dose intensification may assist in regaining response…
Presenter
Geert D’Haens
Speakers
Marla Dubinsky
Icahn School of Medicine, Mount Sinai
Laurent Peyrin-Biroulet
Silvio Danese
Bruce Sands
Douglas Wolf
Andres Yarur
Michael Chiorean
Swedish Medical Center
Danielle Dray
Irene Modesto
Huaming Tan
Guibao Gu
Claudia Lopez
Chinyu Su
Jinkun Zhang
Aoibhinn McDonnell
Stefan Schreiber
Brian Feagan
Western University
Séverine Vermeire
Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven
EFFICACY AND SAFETY OF THE SELECTIVE SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATOR, ETRASIMOD, IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS OVER 52 WEEKS IN THE PHASE 2 VOYAGE STUDY
Date
May 20, 2024
BACKGROUND: Etrasimod is an investigational, oral, once-daily (QD), selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator in development to treat immune-mediated inflammatory disorders…
Presenter
Evan Dellon
University of North Carolina School of Medicine
Speakers
Margaret Collins
Arjan Bredenoord
Amsterdam UMC, University of Amsterdam
Hamish Philpott
Luc Biedermann
Márjori Dulcine
Thai Nguyen-Cleary
Chinyu Su
Jin Yu
Huaming Tan
Fabio Cataldi
Hanzhe Zheng
Wenjin Wang
Pamela Clax
John Woolcott
Ikuo Hirano